Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies

Go back to Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies
Vertex Pharmaceuticals Inc (NASDAQ: VRTX) Delayed: 508.34 -8 (1.55%)
Previous Close $516.34    52 Week High $134.71 
Open $516.34    52 Week Low $73.31 
Day High $518.10    P/E N/A 
Day Low $505.01    EPS $-1.98 
Volume 2,434,829